CDNA · Caredx, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $117.70M | - | $100.06M | $86.68M | $84.69M | - | $82.88M | $92.27M | $72.05M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $21.42M | - | $16.77M | $16.83M | $18.52M | - | $17.49M | $19.68M | $18.71M | - |
| SG&A | $30.48M | - | $28.43M | $27.68M | $22.77M | - | $28.52M | $27.68M | $26.91M | - |
| Total Operating Expenses | $116.50M | - | $100.30M | $97.80M | $98.06M | - | $93.38M | $96.37M | $91.39M | - |
| D&A | $3.90M | - | - | - | $3.60M | - | - | - | $3.82M | - |
| Operating Income | $1.20M | - | ($246.0K) | ($11.12M) | ($13.37M) | - | ($10.49M) | ($4.10M) | ($19.34M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($32.0K) | - | ($15.0K) | ($117.0K) | $58.0K | - | $200.0K | $22.0K | ($83.0K) | - |
| Net Income | $2.81M | - | $1.68M | ($8.57M) | ($10.35M) | - | ($7.41M) | ($1.39M) | ($16.66M) | - |
| EPS - Basic | $0.05 | - | $0.03 | ($0.16) | ($0.19) | - | ($0.14) | ($0.03) | ($0.32) | - |
| EPS - Diluted | $0.05 | - | $0.03 | ($0.16) | ($0.19) | - | ($0.14) | ($0.03) | ($0.32) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.92M | $65.43M | $91.44M | $68.21M | $88.75M | $114.69M | $95.40M | $95.78M | $93.30M | $82.20M |
| Accounts Receivable | $44.59M | $42.63M | $47.84M | $67.36M | $71.48M | $64.61M | $66.63M | $66.16M | $60.15M | $51.06M |
| Inventory | $26.40M | $26.70M | $28.33M | $27.91M | $22.93M | $19.50M | $19.26M | $19.23M | $20.13M | $19.47M |
| Accounts Payable | $9.07M | $9.99M | $11.60M | $9.86M | $8.07M | $7.69M | $6.24M | $5.87M | $9.98M | $12.87M |
| Current Assets | $269.39M | $257.13M | $300.28M | $307.30M | $350.24M | $351.83M | $334.09M | $320.61M | $303.10M | $313.71M |
| Total Assets | $411.06M | $413.23M | $432.31M | $444.26M | $489.64M | $491.05M | $476.99M | $466.78M | $452.41M | $466.83M |
| Current Liabilities | $79.15M | $89.85M | $99.04M | $93.18M | $85.28M | $89.37M | $81.44M | $78.33M | $70.21M | $78.07M |
| Long-term Debt | - | - | - | - | - | - | $0 | $0 | - | - |
| Total Liabilities | $97.53M | $110.13M | $121.17M | $116.89M | $110.29M | $112.62M | $203.74M | $202.11M | $196.18M | $205.50M |
| Stockholders' Equity | $313.54M | $303.10M | $311.14M | $327.37M | $379.35M | $378.43M | $273.25M | $264.67M | $256.23M | $261.33M |
| Retained Earnings | ($732.55M) | ($735.36M) | ($719.05M) | ($695.16M) | ($636.60M) | ($626.24M) | ($704.25M) | ($696.84M) | ($695.45M) | ($678.27M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.33M | - | - | - | ($26.58M) | - | - | - | ($15.31M) | - |
| Investing Cash Flow | $11.06M | - | - | - | $1.32M | - | - | - | $27.66M | - |
| Financing Cash Flow | ($2.91M) | - | - | - | ($643.0K) | - | - | - | ($1.27M) | - |
| CapEx | $1.63M | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | $2.70M | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 1.0% | - | -0.2% | -12.8% | -15.8% | - | -12.7% | -4.4% | -26.8% | - |
| EBITDA margin | 4.3% | - | - | - | -11.5% | - | - | - | -21.5% | - |
| Net margin | 2.4% | - | 1.7% | -9.9% | -12.2% | - | -8.9% | -1.5% | -23.1% | - |
| Free cash flow margin | 2.3% | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.96 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 18.2% | - | 16.8% | 19.4% | 21.9% | - | 21.1% | 21.3% | 26.0% | - |
| SG&A / Revenue | 25.9% | - | 28.4% | 31.9% | 26.9% | - | 34.4% | 30.0% | 37.4% | - |
| Effective tax rate | -1.2% | - | -0.9% | - | - | - | - | - | - | - |
| Return on assets | 0.7% | - | 0.4% | -1.9% | -2.1% | - | -1.6% | -0.3% | -3.7% | - |
| Return on equity | 0.9% | - | 0.5% | -2.6% | -2.7% | - | -2.7% | -0.5% | -6.5% | - |
| Return on invested capital | - | - | - | - | - | - | -3.0% | -1.2% | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.40 | 2.86 | 3.03 | 3.30 | 4.11 | 3.94 | 4.10 | 4.09 | 4.32 | 4.02 |
| Quick ratio | 3.07 | 2.56 | 2.75 | 3.00 | 3.84 | 3.72 | 3.87 | 3.85 | 4.03 | 3.77 |
| Cash ratio | 0.98 | 0.73 | 0.92 | 0.73 | 1.04 | 1.28 | 1.17 | 1.22 | 1.33 | 1.05 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | 0.00 | 0.00 | - | - |
| Debt / Assets | - | - | - | - | - | - | 0.00 | 0.00 | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.31 | 1.36 | 1.39 | 1.36 | 1.29 | 1.30 | 1.75 | 1.76 | 1.77 | 1.79 |
| Liabilities / Assets | 0.24 | 0.27 | 0.28 | 0.26 | 0.23 | 0.23 | 0.43 | 0.43 | 0.43 | 0.44 |
| Efficiency | ||||||||||
| Asset turnover | 0.29 | - | 0.23 | 0.20 | 0.17 | - | 0.17 | 0.20 | 0.16 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 138d | - | 175d | 284d | 308d | - | 293d | 262d | 305d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 347.2x | - | 484.7x | - | - | - | - | - | - | - |
| P / B | 2.9x | - | 2.5x | 3.2x | 2.6x | - | 6.0x | 3.1x | 2.1x | - |
| P / S | 7.8x | - | 7.8x | 12.2x | 11.6x | - | 19.9x | 8.8x | 7.6x | - |
| EV / EBITDA | 165.7x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 39.0% | - | 20.7% | -6.1% | 17.5% | - | 23.4% | 31.3% | -6.7% | - |
| Revenue CAGR (3y) | 15.1% | - | 8.0% | 2.4% | 2.2% | - | 3.1% | 7.5% | 2.2% | - |
| Revenue CAGR (5y) | 11.8% | - | 13.4% | 15.7% | 17.1% | - | 19.6% | 24.0% | 22.6% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 97.7% | -171.4% | 30.8% | - | 63.5% | 85.2% | 20.5% | - |
| Net income growth (YoY) | - | - | - | -514.6% | 37.9% | - | 68.5% | 94.4% | 29.9% | - |
| EPS growth (YoY) | - | - | - | -433.3% | 40.6% | - | 67.4% | 93.5% | 27.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -17.3% | -19.9% | 13.9% | 23.7% | 48.1% | 44.8% | -30.7% | -34.7% | -39.0% | -39.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$379.81M totalReportable Segment$379.81M · 100.0%
Product / service
$379.81M totalService$274.50M · 72.3%
Patient And Digital Solutions$56.93M · 15.0%
Product$48.38M · 12.7%
Geographic
$379.81M totalUS$359.94M · 94.8%
Non Us$19.87M · 5.2%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing CareDx against the 5 most active filers in the same SIC group.